Biogen Inc. (BIIB)

Over the past six months, Biogen's stock price has fluctuated. As of October 3, 2025, the stock was down 13.47% over the past 12 months and 18.29% from October 2, 2024, to October 1, 2025. However, on October 1, 2025, the stock surged by 9.02% due to promising advancements in its Alzheimer's disease drug Leqembi. In Q1 2025, Biogen reported revenues above analyst estimates, driven by strong sales of its rare disease assets, which helped offset a decline in its multiple sclerosis business. The company anticipates a potential biosimilar entry for TYSABRI in the U.S. in the fourth quarter of 2025, which is expected to contribute to a mid-single-digit decline in total revenue for 2025, primarily due to pressures on the MS franchise.

There is evidence of demand seasonality for Biogen's products. The first quarter of the year has historically been a seasonally weaker period for the company's multiple sclerosis (MS) business, influenced by factors such as higher discounts, allowances, and channel dynamics. The company tracks and displays mean and median monthly returns to identify these seasonal patterns, indicating that demand for its products and services can vary throughout the year.

Biogen Inc. is a multinational biotechnology company focused on therapies for neurological and neurodegenerative diseases, operating in the Healthcare sector. Its major products include treatments for multiple sclerosis (MS) like Tecfidera and Spinraza for spinal muscular atrophy (SMA), Skyclarys for Friedreich's ataxia, Qalsody for amyotrophic lateral sclerosis (ALS), and Leqembi for Alzheimer's disease. The company also produces biosimilars and Fumaderm for severe plaque psoriasis.

Biogen has a significant global presence with operations in the United States, Europe, Germany, and Asia, and therapies available in over 80 countries. It maintains a direct affiliate presence in 30 countries and utilizes a network of distribution partners in over 50 additional countries. Its global headquarters are in Cambridge, Massachusetts, U.S., with international headquarters in Baar, Switzerland. Manufacturing facilities are in North Carolina, U.S., and Solothurn, Switzerland. R&D teams are primarily based in Cambridge, MA, and have expanded to South San Francisco, CA.

In the past year, Biogen has maintained its reputation as a leading biotechnology company focused on pioneering science and innovation in neurological and neurodegenerative diseases. Advancements and regulatory approvals for Leqembi have bolstered its brand reputation. The strong performance of its rare disease portfolio has also contributed positively. Biogen's commitment to advancing health equity and ensuring diverse representation in clinical trials further supports its reputation. While the company faces ongoing challenges with declining revenue in its established MS franchise due to generic and biosimilar competition, this appears to be viewed as a market dynamic rather than a direct hit to its overall brand integrity.

Biogen's stock ownership is predominantly institutional, with reported percentages ranging from approximately 52.10% to 88.50%. Major institutional owners include Vanguard Group Inc, Primecap Management Co/ca/, BlackRock, Inc., State Street Corp, and Wellington Management Group Llp. Individual insider ownership is relatively small, around 0.17%.